IDEAYA Biosciences (IDYA) Short Interest Ratio & Short Volume $23.63 -0.49 (-2.03%) Closing price 04:00 PM EasternExtended Trading$23.64 +0.02 (+0.06%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDEAYA Biosciences Short Interest DataIDEAYA Biosciences (IDYA) has a short interest of 11.74 million shares, representing 14.90% of the float (the number of shares available for trading by the public). This marks a 1.38% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.6, indicating that it would take 9.6 days of the average trading volume of 1.11 million shares to cover all short positions.Current Short Interest11,740,000 sharesPrevious Short Interest11,580,000 sharesChange Vs. Previous Month+1.38%Dollar Volume Sold Short$251.59 millionShort Interest Ratio9.6 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares87,580,000 sharesFloat Size78,780,000 sharesShort Percent of Float14.90%Today's Trading Volume846,682 sharesAverage Trading Volume1,110,164 sharesToday's Volume Vs. Average76% Short Selling IDEAYA Biosciences? Sign up to receive the latest short interest report for IDEAYA Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIDYA Short Interest Over TimeIDYA Days to Cover Over TimeIDYA Percentage of Float Shorted Over Time IDEAYA Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202511,740,000 shares $251.59 million +1.4%14.9%9.6 $21.43 6/30/202511,580,000 shares $243.41 million +2.1%14.7%8.5 $21.02 6/15/202511,340,000 shares $251.52 million +8.0%14.4%8 $22.18 5/31/202510,500,000 shares $210.53 million -1.7%13.3%7.4 $20.05 5/15/202510,680,000 shares $184.87 million -1.8%13.6%8 $17.31 4/30/202510,880,000 shares $219.01 million +2.0%13.5%8.6 $20.13 4/15/202510,670,000 shares $181.18 million +7.2%13.2%9 $16.98 3/31/20259,950,000 shares $162.98 million +0.7%12.3%9.5 $16.38 3/15/20259,880,000 shares $183.57 million +7.5%12.2%10.8 $18.58 2/28/20259,190,000 shares $189.04 million +3.3%11.4%10.3 $20.57 Get the Latest News and Ratings for IDYA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. 2/15/20258,900,000 shares $186.90 million -7.1%11.0%9.4 $21.00 1/31/20259,580,000 shares $233.27 million -0.9%12.4%10.4 $24.35 1/15/20259,670,000 shares $224.92 million -3.3%12.5%10.6 $23.26 12/31/202410,000,000 shares $257 million +10.1%12.9%11.2 $25.70 12/15/20249,080,000 shares $228.73 million +1.7%11.7%9.8 $25.19 11/30/20248,930,000 shares $244.32 million -11.2%11.6%10 $27.36 11/15/202410,060,000 shares $268.00 million +8.1%13.0%12.1 $26.64 10/31/20249,310,000 shares $262.08 million -3.1%11.9%13.2 $28.15 10/15/20249,610,000 shares $296.18 million -20.5%12.6%13.8 $30.82 9/30/202412,080,000 shares $382.69 million +3.3%15.8%15 $31.68 9/15/202411,700,000 shares $438.28 million +2.5%15.3%13.3 $37.46 8/31/202411,420,000 shares $451.09 million -1.0%14.9%13.3 $39.50 8/15/202411,540,000 shares $439.79 million -0.9%15.1%11.9 $38.11 7/31/202411,640,000 shares $501.10 million -2.2%15.4%11.5 $43.05 7/15/202411,900,000 shares $492.07 million +1.6%15.9%11.8 $41.35 6/30/202411,710,000 shares $411.14 million +6.1%17.3%12.6 $35.11 6/15/202411,040,000 shares $420.73 million +2.9%16.3%14.6 $38.11 5/31/202410,730,000 shares $392.18 million -3.3%15.9%14.2 $36.55 5/15/202411,090,000 shares $470.66 million +3.8%16.4%15.5 $42.44 4/30/202410,680,000 shares $434.14 million +8.7%16.2%15.2 $40.65 4/15/20249,830,000 shares $408.04 million +4.5%14.9%13.7 $41.51 3/31/20249,410,000 shares $412.91 million +6.7%14.3%10.4 $43.88 3/15/20248,820,000 shares $390.73 million +3.0%13.6%9.6 $44.30 2/29/20248,560,000 shares $382.63 million +2.6%13.2%8.7 $44.70 2/15/20248,340,000 shares $387.31 million +4.1%12.8%8.4 $46.44 1/31/20248,010,000 shares $348.68 million +1.4%12.4%7.9 $43.53 1/15/20247,900,000 shares $313.95 million -5.5%13.0%7.2 $39.74 12/31/20238,360,000 shares $297.45 million -0.4%15.1%9.1 $35.58 12/15/20238,390,000 shares $294.24 million -2.9%15.1%9.3 $35.07 11/30/20238,640,000 shares $271.73 million +2.4%16.1%11.1 $31.45Green Light for These Stocks (Ad)Guess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... becoming the largest shareholder in a critical mineral company tied to national security. Former hedge fund manager Whitney Tilson believes this is just the start of a sweeping plan to unlock trillions in hidden federal assets... from oil-rich land to rare earths and energy reserves. He says this could mark the beginning of the largest wealth transfer in modern U.S. history, and has identified the surprising areas where you could benefit.Click here to see how to position yourself before a looming federal deadline that's now just weeks a 11/15/20238,440,000 shares $250.33 million +9.0%15.7%11.5 $29.66 10/31/20237,740,000 shares $210.30 million +15.5%14.6%10.7 $27.17 10/15/20236,700,000 shares $167.43 million -10.3%13.7%11.7 $24.99 9/30/20237,470,000 shares $201.54 million +5.2%15.2%15.4 $26.98 9/15/20237,100,000 shares $207.11 million +4.3%14.5%15 $29.17 8/31/20236,810,000 shares $199.94 million +4.5%13.3%13.5 $29.36 8/15/20236,520,000 shares $167.04 million +8.5%12.7%12.5 $25.62 7/31/20236,010,000 shares $134.38 million -1.6%11.9%11.2 $22.36 7/15/20236,110,000 shares $138.51 million +1.5%12.1%8.1 $22.67 6/30/20236,020,000 shares $141.47 million +25.7%12.0%8 $23.50 6/15/20234,790,000 shares $119.46 million +3.7%9.5%6.3 $24.94 5/31/20234,620,000 shares $105.52 million +0.9%9.2%6.6 $22.84 5/15/20234,580,000 shares $99.16 million No Change9.1%7 $21.65 10/31/20224,830,000 shares $81.58 million +0.8%N/A8.8 $16.89 10/15/20224,790,000 shares $74.58 million +12.7%N/A9.3 $15.57 9/30/20224,250,000 shares $63.41 million +17.1%N/A8.8 $14.92 9/15/20223,630,000 shares $42.69 million +4.0%N/A8.5 $11.76 8/31/20223,490,000 shares $34.31 million -1.4%11.5%9.5 $9.83 8/15/20223,540,000 shares $36.11 million -2.5%11.8%10.7 $10.20 7/31/20223,630,000 shares $54.16 million -2.2%12.1%13.2 $14.92 7/15/20223,710,000 shares $57.51 million -2.9%12.4%12.9 $15.50 6/30/20223,820,000 shares $52.72 million -4.7%12.8%12.5 $13.80 6/15/20224,010,000 shares $49.08 million -5.2%13.4%12.9 $12.24 5/31/20224,230,000 shares $47.16 million +0.2%14.1%13.1 $11.15 5/15/20224,220,000 shares $44.18 million +11.6%14.1%11.2 $10.47 4/30/20223,780,000 shares $36.25 million +5.3%12.8%10.1 $9.59 4/15/20223,590,000 shares $38.84 million +0.8%12.2%9.8 $10.82 3/31/20223,560,000 shares $39.84 million -5.8%N/A9.4 $11.19 3/15/20223,780,000 shares $44.94 million +0.3%N/A10.1 $11.89 2/28/20223,770,000 shares $49.76 million -1.6%12.8%10.3 $13.20 2/15/20223,830,000 shares $57.41 million +7.9%13.0%11.8 $14.99 1/31/20223,550,000 shares $58.82 million +10.9%12.1%11 $16.57 1/15/20223,200,000 shares $57.02 million +10.0%N/A9.9 $17.82 12/31/20212,910,000 shares $68.79 million +17.8%9.3%9.4 $23.64 12/15/20212,470,000 shares $54.56 million -1.6%7.9%7.6 $22.09 11/30/20212,510,000 shares $55.22 million No Change8.0%7.4 $22.00 11/15/20212,510,000 shares $58.66 million +2.5%8.0%7.7 $23.37 10/29/20212,450,000 shares $52.53 million +6.1%7.8%8.1 $21.44 10/15/20212,310,000 shares $53.43 million -11.2%7.4%7.4 $23.13 9/30/20212,600,000 shares $66.27 million +31.3%8.3%8.1 $25.49 9/15/20211,980,000 shares $51.68 million -6.2%6.3%5.7 $26.10 8/31/20212,110,000 shares $49.59 million -7.5%6.8%7.2 $23.50 8/13/20212,280,000 shares $53.44 million -1.3%7.3%9.2 $23.44 7/30/20212,310,000 shares $56.60 million +22.2%7.7%9.7 $24.50 7/15/20211,890,000 shares $35.29 million +24.3%6.6%9 $18.67 6/30/20211,520,000 shares $31.90 million +22.6%5.3%7.3 $20.99 6/15/20211,240,000 shares $27.34 million -1.6%5.0%8.3 $22.05 5/28/20211,260,000 shares $25.39 million +5.9%5.1%7.9 $20.15 5/14/20211,190,000 shares $22.34 million +11.2%N/A6.6 $18.77 4/30/20211,070,000 shares $22.00 million +67.7%N/A5.9 $20.56Green Light for These Stocks (Ad)Guess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... becoming the largest shareholder in a critical mineral company tied to national security. Former hedge fund manager Whitney Tilson believes this is just the start of a sweeping plan to unlock trillions in hidden federal assets... from oil-rich land to rare earths and energy reserves. He says this could mark the beginning of the largest wealth transfer in modern U.S. history, and has identified the surprising areas where you could benefit.Click here to see how to position yourself before a looming federal deadline that's now just weeks a 4/15/2021637,900 shares $11.99 million +5.5%N/A0 $18.79 3/31/2021604,600 shares $13.85 million +1.9%N/A2.8 $22.90 3/15/2021593,500 shares $13.62 million -16.3%N/A2.8 $22.95 2/26/2021709,000 shares $12.89 million +2.3%N/A3.3 $18.18 2/12/2021693,300 shares $13.37 million +0.5%N/A3.3 $19.29 1/29/2021689,700 shares $11.73 million -1.4%3.6%3.1 $17.01 1/15/2021699,700 shares $11.43 million -16.5%3.7%2.8 $16.34 12/31/2020838,000 shares $10.68 million +21.6%4.4%3.9 $12.75 12/15/2020689,100 shares $9.59 million -4.5%3.7%3.8 $13.92 11/30/2020721,200 shares $9.78 million -38.9%4.2%4.1 $13.56 11/15/20201,180,000 shares $15.76 million +62.1%6.9%7 $13.36 10/30/2020728,000 shares $8.99 million -1.0%4.5%4.4 $12.35 10/15/2020735,000 shares $9.99 million +7.0%4.5%4.4 $13.59 9/30/2020687,000 shares $8.63 million +17.9%N/A4 $12.56 9/15/2020582,700 shares $7.45 million +1.4%3.6%2.6 $12.79 8/31/2020574,800 shares $6.96 million -2.8%3.5%1.7 $12.10 8/14/2020591,100 shares $6.95 million -0.5%3.8%1.8 $11.75 IDYA Short Interest - Frequently Asked Questions What is IDEAYA Biosciences' current short interest? Short interest is the volume of IDEAYA Biosciences shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 11,740,000 shares of IDYA short. 14.90% of IDEAYA Biosciences' shares are currently sold short. Learn More on IDEAYA Biosciences' current short interest. What is a good short interest ratio for IDEAYA Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IDYA shares currently have a short interest ratio of 10.0. Learn More on IDEAYA Biosciences's short interest ratio. What is a good short interest percentage for IDEAYA Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.90% of IDEAYA Biosciences' floating shares are currently sold short. Is IDEAYA Biosciences' short interest increasing or decreasing? IDEAYA Biosciences saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 11,740,000 shares, an increase of 1.4% from the previous total of 11,580,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is IDEAYA Biosciences' float size? IDEAYA Biosciences currently has issued a total of 87,580,000 shares. Some of IDEAYA Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. IDEAYA Biosciences currently has a public float of 78,780,000 shares. How does IDEAYA Biosciences' short interest compare to its competitors? 14.90% of IDEAYA Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to IDEAYA Biosciences: Verona Pharma PLC American Depositary Share (4.77%), Blueprint Medicines Corporation (5.95%), Legend Biotech Corporation Sponsored ADR (4.57%), Roivant Sciences Ltd. (10.56%), Regencell Bioscience Holdings Limited (9.57%), Elanco Animal Health Incorporated (4.75%), Revolution Medicines, Inc. (7.33%), Grifols, S.A. (0.96%), TG Therapeutics, Inc. (15.22%), Nuvalent, Inc. (12.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short IDEAYA Biosciences stock? Short selling IDYA is an investing strategy that aims to generate trading profit from IDEAYA Biosciences as its price is falling. IDYA shares are trading down $0.49 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against IDEAYA Biosciences? A short squeeze for IDEAYA Biosciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IDYA, which in turn drives the price of the stock up even further. How often is IDEAYA Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IDYA, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies Verona Pharma PLC American Depositary Share Short Interest Blueprint Medicines Short Interest Legend Biotech Short Interest Roivant Sciences Short Interest Regencell Bioscience Short Interest Elanco Animal Health Short Interest Revolution Medicines Short Interest Grifols Short Interest TG Therapeutics Short Interest Nuvalent Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IDYA) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredInstant Cash (every 3rd Monday)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
